This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Veeva Systems (VEEV) Stock Moves -0.88%: What You Should Know
by Zacks Equity Research
In the latest trading session, Veeva Systems (VEEV) closed at $87.08, marking a -0.88% move from the previous day.
Here's Why You Should Invest in STERIS (STE) Stock Right Now
by Zacks Equity Research
With the acquisition of U.K.-based outsourced sterilization services provider Synergy Health, STERIS (STE) has become the global leader in infection prevention and sterilization.
Abercrombie, Halliburton, Veeva, Attunity and Nice highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Abercrombie, Halliburton, Veeva, Attunity and Nice highlighted as Zacks Bull and Bear of the Day
Medtronic's Mazor Buyout Creates a New Spine Surgery Major
by Zacks Equity Research
With the acquisition of Mazor Robotics, Medtronic (MDT) expects to offer a fully-integrated procedural solution for surgical planning, execution and confirmation.
3 Cloud Stocks to Buy Right Now
by Ryan McQueeney
In a matter of just a few years, "the Cloud" has evolved from a budding new tech feature to one of the main factors driving growth in the technology sector. Check out these three cloud stocks to buy right now!
Veeva, Party City, Mellanox, Cree and Intel highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Veeva, Party City, Mellanox, Cree and Intel highlighted as Zacks Bull and Bear of the Day
GNC Holdings Global Business Strong, Same Store Sales Weak
by Zacks Equity Research
GNC Holdings' (GNC) domestic franchise revenues worsen due to soft retail same store sales and fewer franchise stores.
Here's Why You Should Buy Haemonetics (HAE) Stock Right Now
by Zacks Equity Research
Haemonetics (HAE) continues to witness strong growth in Plasma franchise.
Bull of the Day: Veeva Systems (VEEV)
by Madeleine Johnson
Estimates are swinging higher for this booming SaaS stock.
4 Medical Device Stocks That More Than Doubled in 2018
by Sweta Jaiswal
Here are four medical device stocks which have performed really well in 2018 and should be on investors' radar next year as well.
Hologic's (HOLX) New Offering to Revitalize Cynosure Division
by Zacks Equity Research
The latest launch along with certain new developments is expected to boost top-line contribution from Hologic's (HOLX) Cynosure division in the near term.
Bruker Profits from NANO & CALID, New Buyout Holds Promise
by Zacks Equity Research
Bruker (BRKR) looks to gain from high demand for ADVANCE X-ray and nano-analysis products. The CALID Group also raises hope with high-single digit robust year-to-date revenues.
Veeva Systems (VEEV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Veeva Systems (VEEV) closed the most recent trading day at $92.13, moving +0.1% from the previous trading session.
Thermo Fisher (TMO) Rides on New Buyouts and APAC Strength
by Zacks Equity Research
We are upbeat about Thermo Fisher's (TMO) recent buyout of Advanced Bioprocessing business, which will add complementary cell culture products to the company's bioproduction suit.
Edwards Lifesciences Advances in AI With Bay Labs Tie-Up
by Zacks Equity Research
Through the tie-up, Edwards Lifesciences (EW) aims at improving detection of heart diseases and enhancing quality by using Bay Labs' ability to apply AI to cardiovascular imaging.
CVS Health Aetna Synergy Impressive, PBM Selling Season Solid
by Zacks Equity Research
CVS Health (CVS) estimates a $750-million earning from near-term synergies with low- to mid-single digit addition in the second year after the closure of Aetna transaction.
STERIS Rides on Favorable Industry Trends, Rivalry a Concern
by Zacks Equity Research
STERIS (STE) is currently displaying strong top-line growth on encouraging market trends along with a new product and service portfolio.
NuVasive's Monolith Corpectomy System Ok'd for Expanded Use
by Zacks Equity Research
NuVasive's (NUVA) latest FDA 510 (k) clearance receipt is expected to augment customer base and market reach.
Hologic Unveils Omni Hysteroscope, Boosts GYN Surgical Arm
by Zacks Equity Research
Hologic (HOLX) highlights that a direct visualization of the uterine cavity in women with abnormal uterine bleeding will set a benchmark for the medical test.
Hill-Rom Adds New Capabilities to Centrella Smart+ Beds
by Zacks Equity Research
Hill-Rom (HRC) stays focused on expansion through product development. The latest move is expected to boost the top-line results of the company.
Here's Why You Should Buy Myriad Genetics (MYGN) Stock Now
by Zacks Equity Research
Myriad Genetics (MYGN) see strong testing volumes from new products.
Insulet Gains on Omnipod Reimbursement Update, Rivalry Stiff
by Zacks Equity Research
Insulet Corporation (PODD) continues to expand Omnipod's market access on growing reimbursements. The company operates in a highly competitive environment.
Myriad Genetics Announces Encouraging EndoPredict Test Data
by Zacks Equity Research
Myriad Genetics (MYGN) forges ahead with initiatives to boost the adoption of the EndoPredict tests.
Illumina (ILMN) Takes Part in NIH Program With Genotype Launch
by Zacks Equity Research
The new Infinium Global Diversity Array of Illumina (ILMN) will process up to 1 million cost-free samples to the three genome centers.
Has Veeva Systems (VEEV) Outpaced Other Computer and Technology Stocks This Year?
by Zacks Equity Research
Is (VEEV) Outperforming Other Computer and Technology Stocks This Year?